Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
Go back to Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 14.87 -0.43 (2.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.30 | 52 Week High | $117.12 | |||
| Open | $15.10 | 52 Week Low | $46.52 | |||
| Day High | $15.25 | P/E | N/A | |||
| Day Low | $14.63 | EPS | $-1.97 | |||
| Volume | 1,077,107 | |||||
